Latest Breaking News On - Lifesci advisors - Page 11 : comparemela.com

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Joyce allaireProspectus departmentExchange commissionErasca incJp morgan securitiesBroadridge financial solutionsLifesci advisorsAnnounces closingUnderwritten offeringCommon stockFull exerciseUnderwriter optionPurchase additionalBofa securitiesIsland avenueTryon street

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares - Erasca (NASDAQ:ERAS)

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with

Joyce allaireProspectus departmentBroadridge financial solutionsJp morgan securitiesExchange commissionLifesci advisorsErasca incBofa securitiesIsland avenueTryon streetPrivate securities litigation reform actSci advisors

Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants

CAMBRIDGE, Mass., May 20, 2024 Foghorn Therapeutics Inc. today announced the pricing of a registered direct offering of 12,743,039 shares of its common stock at a price of $5.51 per share,.

New yorkUnited statesUnited kingdomAdam silversteinPeter kelleherGreg dearbornKarin hellsvikTd securities united statesExchange commissionEvercore groupCompany annual report on formEquity syndicate prospectus departmentFoghorn therapeutics incEquity capital marketsGene trafficAnnual report

Erasca Announces Strategic In-Licensing of RAS-Targeting

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors .

Hong kongUnited statesJoyce allaireExchange commissionJoyo pharmatech co ltdMedshine discovery incLifesci advisorsErasca incLicensed programsNew drug applicationMedshine discoveryPipeline prioritizationPrivate securities litigation reform actSci advisors

Erasca Announces Pricing of Underwritten Offering of Common Stock

Erasca Announces Pricing of Underwritten Offering of Common Stock
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Joyce allaireBroadridge financial solutionsProspectus departmentExchange commissionErasca incJp morgan securitiesLifesci advisorsAnnounces pricingUnderwritten offeringBofa securitiesIsland avenueTryon streetPrivate securities litigation reform actSci advisors